| Brooke Nowak, | |
|
528 E University Dr, Auburn, AL 36830-6850 | |
| (832) 723-2920 | |
| Not Available |
| Full Name | Brooke Nowak |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Counseling |
| Location | 528 E University Dr, Auburn, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366991119 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC1900X | Psychologist - Counseling | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brooke Nowak, 528 E University Dr, Auburn, AL 36830-6850 Ph: () - | Brooke Nowak, 528 E University Dr, Auburn, AL 36830-6850 Ph: (832) 723-2920 |
News Archive
In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients.
One of the largest studies to date on nuts and diabetes was published today in Diabetologia, the journal of the European Association for the Study of Diabetes. The study shows that approximately two ounces of nuts a day, as a replacement for carbohydrate foods, can improve glycemic control and blood lipids in those with type 2 diabetes.
Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.
Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).
› Verified 7 days ago
Dr. Jennings B. Haynes, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2431 E Glenn Ave Ste 400, Auburn, AL 36830 Phone: 334-377-4900 Fax: 334-377-4901 | |
Dr. Nicole Linen, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 311 N. College St, Auburn, AL 36830 Phone: 334-219-0425 | |
Dr. Beatrice Charmaine Mosier, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1983 Stephanie Ct, Auburn, AL 36830 Phone: 334-207-4339 | |
Dr. Thomas Howard Lawry, PH.D. Psychologist Medicare: May Accept Medicare Assignments Practice Location: 248 E Glenn Ave, Auburn, AL 36830 Phone: 334-821-3350 Fax: 334-821-3252 | |
Dr. Peggy Howland, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 248 E Glenn Ave, Auburn, AL 36830 Phone: 334-821-3350 Fax: 334-821-3252 | |
Dr. Page Walley, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 248 E Glenn Ave, Auburn, AL 36830 Phone: 334-821-3350 Fax: 334-821-3252 | |
Dr. Jennifer Gillis Mattson, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1897 Quail Holw, Auburn, AL 36830 Phone: 607-760-2550 |